China · Delayed Price · Currency is CNY Kexing Biopharm Statistics
Total Valuation
Kexing Biopharm has a market cap or net worth of CNY 5.15 billion. The enterprise value is 5.94 billion.
| Market Cap | 5.15B |
| Enterprise Value | 5.94B |
Important Dates
The last earnings date was Wednesday, April 22, 2026.
| Earnings Date | Apr 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kexing Biopharm has 198.06 million shares outstanding. The number of shares has increased by 0.67% in one year.
| Current Share Class | 198.06M |
| Shares Outstanding | 198.06M |
| Shares Change (YoY) | +0.67% |
| Shares Change (QoQ) | +4.00% |
| Owned by Insiders (%) | 50.50% |
| Owned by Institutions (%) | 12.72% |
| Float | 98.08M |
Valuation Ratios
The trailing PE ratio is 45.87 and the forward PE ratio is 41.97.
| PE Ratio | 45.87 |
| Forward PE | 41.97 |
| PS Ratio | 3.53 |
| PB Ratio | 2.98 |
| P/TBV Ratio | 3.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 76.35 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 37.47, with an EV/FCF ratio of -282.17.
| EV / Earnings | 52.98 |
| EV / Sales | 4.06 |
| EV / EBITDA | 37.47 |
| EV / EBIT | 104.26 |
| EV / FCF | -282.17 |
Financial Position
The company has a current ratio of 1.50, with a Debt / Equity ratio of 0.82.
| Current Ratio | 1.50 |
| Quick Ratio | 1.26 |
| Debt / Equity | 0.82 |
| Debt / EBITDA | 9.01 |
| Debt / FCF | -67.03 |
| Interest Coverage | 1.11 |
Financial Efficiency
Return on equity (ROE) is 6.44% and return on invested capital (ROIC) is 2.27%.
| Return on Equity (ROE) | 6.44% |
| Return on Assets (ROA) | 0.89% |
| Return on Invested Capital (ROIC) | 2.27% |
| Return on Capital Employed (ROCE) | 1.93% |
| Weighted Average Cost of Capital (WACC) | 5.81% |
| Revenue Per Employee | 1.54M |
| Profits Per Employee | 118,325 |
| Employee Count | 971 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 4.03 |
Taxes
| Income Tax | -1.26M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.57% in the last 52 weeks. The beta is 0.45, so Kexing Biopharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -25.57% |
| 50-Day Moving Average | 29.05 |
| 200-Day Moving Average | 36.20 |
| Relative Strength Index (RSI) | 39.61 |
| Average Volume (20 Days) | 5,861,257 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kexing Biopharm had revenue of CNY 1.46 billion and earned 112.05 million in profits. Earnings per share was 0.57.
| Revenue | 1.46B |
| Gross Profit | 894.26M |
| Operating Income | 47.42M |
| Pretax Income | 108.08M |
| Net Income | 112.05M |
| EBITDA | 145.45M |
| EBIT | 47.42M |
| Earnings Per Share (EPS) | 0.57 |
Balance Sheet
The company has 628.04 million in cash and 1.41 billion in debt, with a net cash position of -782.12 million or -3.95 per share.
| Cash & Cash Equivalents | 628.04M |
| Total Debt | 1.41B |
| Net Cash | -782.12M |
| Net Cash Per Share | -3.95 |
| Equity (Book Value) | 1.73B |
| Book Value Per Share | 8.67 |
| Working Capital | 516.05M |
Cash Flow
In the last 12 months, operating cash flow was 67.50 million and capital expenditures -88.54 million, giving a free cash flow of -21.04 million.
| Operating Cash Flow | 67.50M |
| Capital Expenditures | -88.54M |
| Depreciation & Amortization | 100.94M |
| Net Borrowing | 151.76M |
| Free Cash Flow | -21.04M |
| FCF Per Share | -0.11 |
Margins
Gross margin is 61.21%, with operating and profit margins of 3.25% and 7.67%.
| Gross Margin | 61.21% |
| Operating Margin | 3.25% |
| Pretax Margin | 7.40% |
| Profit Margin | 7.67% |
| EBITDA Margin | 9.96% |
| EBIT Margin | 3.25% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.25, which amounts to a dividend yield of 0.94%.
| Dividend Per Share | 0.25 |
| Dividend Yield | 0.94% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 51.24% |
| Buyback Yield | -0.67% |
| Shareholder Yield | 0.33% |
| Earnings Yield | 2.17% |
| FCF Yield | -0.41% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |